Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 71
- 试验地点
- 1
- 主要终点
- Clinical pregnancy
研究概览
简要总结
Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).
详细描述
Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood supply. These effects are of potential benefit for implantation support during IVF-ET cycles.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •had repeated implantation failure
- •have at least 1 good quality embryo for transfer
排除标准
- •uterine abnormalities that could compromise the implantation process (e.g. fibroids, endometrial polyp, bicornuate uterus, adhesion of uterine cavity)
研究组 & 干预措施
Atosiban
干预措施: atosiban (Drug)
结局指标
主要结局
Clinical pregnancy
时间窗: 5 weeks after intervention
次要结局
未报告次要终点
研究者
Vuong Thi Ngoc Lan
Lecturer and Researcher, Department of Obstetrics and Gynecology
University of Medicine and Pharmacy at Ho Chi Minh City